Table 1 Baseline demographic and disease characteristics in the overall population (as-treated analysis)
Characteristic | Abatacept + MTX (n = 40) | Adalimumab + MTX (n = 40) | Total (N = 80) |
|---|---|---|---|
Demographic characteristics | |||
 Age, years | 47.2 (12.2) | 44.7 (16.3) | 46.0 (14.4) |
 Weight, kg | 75.8 (16.8) | 67.9 (16.9) | 71.8 (17.2) |
 Female, n (%) | 29 (72.5) | 31 (77.5) | 60 (75.0) |
 Race, n (%) | |||
  White | 36 (90.0) | 36 (90.0) | 72 (90.0) |
  Black/African American | 4 (10.0) | 1 (2.5) | 5 (6.3) |
  Asian | 0 | 2 (5.0) | 2 (2.5) |
  Other | 0 | 1 (2.5) | 1 (1.3) |
 Ethnicity, n (%)* | |||
  Hispanic/Latino | 4 (10.0) | 6 (15.0) | 10 (12.5) |
  Non-Hispanic/Latino | 16 (40.0) | 14 (35.0) | 30 (37.5) |
Disease characteristics | |||
 Disease duration, months | 5.4 (2.4) | 5.5 (2.9) | 5.5 (2.6) |
 Tender joint count, 68 joints | 18.7 (16.1) | 19.7 (15.2) | 19.2 (15.6) |
 Swollen joint count, 66 joints | 13.6 (12.7) | 13.1 (8.9) | 13.3 (10.9) |
 Tender joint count, 28 joints | 11.5 (7.9) | 12.9 (6.8) | 12.2 (7.3) |
 Swollen joint count, 28 joints | 10.0 (6.8) | 10.1 (5.6) | 10.0 (6.2) |
 Patient pain assessment, VAS (100 mm) | 64.8 (19.0) | 64.3 (24.2) | 64.5 (21.6) |
 HAQ-DI | 1.3 (0.8) | 1.4 (0.8) | 1.3 (0.8) |
 Patient global assessment, VAS (100 mm) | 61.3 (20.2) | 57.2 (25.3) | 59.3 (22.8) |
 Physician global assessment, VAS (100 mm) | 56.9 (20.0) | 60.8 (18.2) | 58.9 (19.1) |
 CRP, mg/L | 12.7 (17.3) | 14.0 (30.7) | 13.4 (24.8) |
 RF-positive, n (%) | 39 (97.5) | 39 (97.5) | 78 (97.5) |
 RF level, U/mL | 139.5 (123.8) | 124.7 (115.0) | 132.1 (119.0) |
 DAS28 (CRP) | 5.2 (1.1) | 5.2 (1.2) | 5.2 (1.1) |
 SDAI | 34.5 (16.1) | 36.1 (15.3) | 35.3 (15.6) |
 CDAI | 33.3 (15.2) | 34.7 (13.8) | 34.0 (14.4) |
 Anti-CCP2 level, U/mL | 991.8 (1104.8) | 1043.1 (1643.3) | 1017.4 (1391.5) |
Concomitant medication | |||
 NSAIDs, n (%) | 27 (67.5) | 31 (77.5) | 58 (72.5) |
 DMARDs | |||
  MTX, n (%) | 40 (100.0) | 40 (100.0) | 80 (100.0) |
  MTX dose, mg/week | 16.6 (3.4) | 17.4 (4.1) | 17.0 (3.8) |
 Biologics, n (%) | 0 | 0 | 0 |
 Corticosteroids | |||
  Oral and/or injectable, n (%) | 24 (60.0) | 22 (55.0) | 46 (57.5) |
  Oral, n (%) | 24 (60.0) | 22 (55.0) | 46 (57.5) |
  Oral dose, mg/day | 6.5 (2.9) | 6.4 (2.8) | 6.4 (2.8) |